biostudies-literatureAdeniji NAmerican College of GastroenterologyNational Cancer InstituteNCI NIH HHS684-698https://www.ebi.ac.uk/biostudies/studies/S-EPMC8140549biostudies-literatureUnknown27(5)The incidence of hepatocellular carcinoma (HCC) is growing in the United States, especially among the elderly. Older patients are increasingly receiving transplants as a result of HCC, but the impact of advancing age on long-term posttransplant outcomes is not clear. To study this, we used data from the US Multicenter HCC Transplant Consortium of 4980 patients. We divided the patients into 4 groups by age at transplantation: 18 to 64 years (n = 4001), 65 to 69 years (n = 683), 70 to 74 years (n = 252), and ≥75 years (n = 44). There were no differences in HCC tumor stage, type of bridging locoregional therapy, or explant residual tumor between the groups. Older age was confirmed to be an independent and significant predictor of overall survival even after adjusting for demographic, etiologiLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyPosttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non-Hepatocellular Carcinoma Factors.PMC8140549K08 CA222676Junior Faculty Career Development AwardBusuttil RWBerumen JSchnickel GTMannalithara AFlorman SSMobley CKwo PVachharajani NGhobrial MHaydel BSudan DLHong JCTevar ADRana ALee DDAhmed AHoteit MAChapman WCRuiz RMBurcin Taner CMelcher MLLangnas ANAgopian VHumar AArjunan VNydam TLGhaziani TCarney CANguyen MFishbein TMDhanasekaran RJones CMAdeniji NVerna ECAucejo FHalazun KJMarkmann JFPrabhakar VKlintmalm GBfalsePosttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non-Hepatocellular Carcinoma Factors.The incidence of hepatocellular carcinoma (HCC) is growing in the United States, especially among the elderly. Older patients are increasingly receiving transplants as a result of HCC, but the impact of advancing age on long-term posttransplant outcomes is not clear. To study this, we used data from the US Multicenter HCC Transplant Consortium of 4980 patients. We divided the patients into 4 groups by age at transplantation: 18 to 64 years (n = 4001), 65 to 69 years (n = 683), 70 to 74 years (n = 252), and ≥75 years (n = 44). There were no differences in HCC tumor stage, type of bridging locoregional therapy, or explant residual tumor between the groups. Older age was confirmed to be an independent and significant predictor of overall survival even after adjusting for demographic, etiologi2021-01-01T00:00:00Z2021 May2025-04-19T13:19:00.01Z2025-04-19T13:19:00.01ZS-EPMC81405493330625410.1002/lt.25974